Drug Profile
15S-hydroxyeicosatrienoic acid - DS Biopharma
Alternative Names: DGLA - second generation; Dihomogammalinolenic-acid - second generation; DS 109; DS 109ALatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Dignity Sciences
- Developer DS Biopharma
- Class Eicosanoids; Omega-6 fatty acids; Skin disorder therapies; Small molecules; Unsaturated fatty acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders; Unspecified
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Unspecified in Ireland (Topical)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Unspecified in Ireland (PO)
- 03 Sep 2019 Phase-I clinical trials in Unspecified in Ireland (Topical) before September 2019 (DS Biopharma pipeline, September 2019)